Swiss contract drugmaker Lonza (SIX: LONN) announced Tuesday it will acquire five manufacturing sites in the United States from Germany’s Merck KGaA, more than doubling its US operational network to nine sites and substantially scaling its capacity for targeted oncology and advanced cell & gene therapies.
📌 Key Deal Metrics & Financial Projections:
• Purchase Valuation: Priced around the midpoint of 100M to 600M Swiss francs ($122M to $734M).
• Revenue Trajectory: Lonza projects the acquired facilities will deliver ~250 million francs in annual revenue by 2028, reaching peak revenue and operational profitability by the mid-2030s.
• Workforce & Geographic Footprint: Adds roughly 1,100 specialized personnel across five manufacturing assets situated in Missouri, Wisconsin, Indiana, and California.
• Closing Timeline: The transaction is slated for formal completion by mid-2027.
📌 Strategic Capabilities & Onshoring Dynamics:
• Clinical Oncology & High-Potency Focus: The two flagship Wisconsin facilities provide critical scale for highly potent active pharmaceutical ingredients (HPAPIs) and advanced cancer therapies, plugging clinical manufacturing gaps in Lonza’s domestic pipeline.
• US Onshoring Alignment: The move aligns with federal policy pushes under the Trump administration prioritizing domestic biopharma supply chain resilience and local manufacturing infrastructure.
• Portfolio Streamlining for Merck KGaA: For Merck KGaA, the divestiture monetizes CDMO assets to sharpen corporate focus on core life sciences and proprietary drug discovery.
💡 Market Takeaway: Biopharma supply chains are rapidly regionalizing. By acquiring established, highly regulated clinical assets rather than building greenfield facilities, Lonza secures immediate high-margin capacity to serve US biotech demand while mitigating long-lead regulatory risk.